NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment

Core Insights - NeOnc Technologies Holdings, Inc. has signed a definitive agreement for a $50 million strategic partnership with Quazar Investment, aimed at advancing treatments for brain and central nervous system cancers [2][3][4] Company Overview - NeOnc is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system cancers, utilizing its proprietary NEO™ drug development platform [6] - The company has a portfolio of novel drug candidates, including NEO100™ and NEO212™, which are currently in Phase II clinical trials under FDA Fast-Track and Investigational New Drug status [6] Strategic Partnership Details - The agreement includes Quazar acquiring 1.4 million shares of NeOnc at $25 per share, totaling $35 million, with an additional $15 million allocated for Phase 2B clinical trials and infrastructure development in the UAE and MENA region [4] - Quazar plans to lead a capital formation round of up to $50 million, with 70% of proceeds directed towards acquiring NeOnc common stock and 30% for clinical trials and infrastructure [4] Future Plans and Conditions - NeOnc must fulfill certain conditions within 120 days, including the legal formation of NuroMENA and NuroCure in Abu Dhabi, for the transaction to be completed [5]